Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Apoptosis

Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL

Abstract

Constitutively activated signaling pathways contribute to the apoptosis-defect of B-CLL cells. Protein kinase C-δ is a permanently activated kinase and a putative downstream target of phosphatidylinositol-3 kinase in B-CLL. Blockade of protein kinase C-δ (PKC-δ) by the highly specific inhibitor rottlerin induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. By co-culturing bone marrow stromal and CLL cells, we determined that the proapoptotic effect of rottlerin is not abolished in the presence of survival factors, indicating that a targeted therapy against PKC-δ might be a powerful approach for the treatment of CLL patients. The downstream events following rottlerin treatment engage mitochondrial and non-mitochondrial pathways and ultimately activate caspases that execute the apoptotic cell death. Herein we report that the inhibition of PKC-δ decreases the expression of the important antiapoptotic proteins Mcl-1 and XIAP accompanied by a loss of the mitochondrial membrane potential Δψ. In addition, we discovered that ZAP-70-expressing cells are significantly more susceptible to rottlerin-induced cell death than ZAP-70 negative cells. We finally observed that rottlerin can augment cell toxicity induced by standard chemotherapeutic drugs. Conclusively, PKC-δ is a promising new target in the combat against CLL.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345.

    CAS  Article  PubMed  Google Scholar 

  2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    CAS  Article  PubMed  Google Scholar 

  3. Caligaris-Cappio F, Hamblin TJ . B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17: 399–408.

    CAS  Article  PubMed  Google Scholar 

  4. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ . Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200–2206.

    CAS  Article  PubMed  Google Scholar 

  5. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002; 100: 3741–3748.

    CAS  Article  PubMed  Google Scholar 

  6. Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T . Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol 2003; 31: 218–225.

    CAS  Article  PubMed  Google Scholar 

  7. Napolitano MJ, Shain DH . Quantitating adenylate nucleotides in diverse organisms. J Biochem Biophys Methods 2005; 63: 69–77.

    CAS  Article  PubMed  Google Scholar 

  8. Mackman N, Brand K, Edgington TS . Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med 1991; 174: 1517–1526.

    CAS  Article  PubMed  Google Scholar 

  9. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV . Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996; 92: 97–103.

    CAS  Article  PubMed  Google Scholar 

  10. Caligaris-Cappio F . Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380–388.

    Article  PubMed  Google Scholar 

  11. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.

    CAS  PubMed  Google Scholar 

  12. Reed JC . Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451–473.

    CAS  Article  PubMed  Google Scholar 

  13. Deveraux QL, Takahashi R, Salvesen GS, Reed JC . X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300–304.

    CAS  Article  PubMed  Google Scholar 

  14. Kitada S, Zapata JM, Andreeff M, Reed JC . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393–397.

    CAS  PubMed  Google Scholar 

  15. Soltoff SP . Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase Cdelta tyrosine phosphorylation. J Biol Chem 2001; 276: 37986–37992.

    CAS  PubMed  Google Scholar 

  16. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  17. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.

    CAS  Article  PubMed  Google Scholar 

  18. Parekh D, Ziegler W, Yonezawa K, Hara K, Parker PJ . Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem 1999; 274: 34758–34764.

    CAS  Article  PubMed  Google Scholar 

  19. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ . Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998; 281: 2042–2045.

    CAS  Article  PubMed  Google Scholar 

  20. Li W, Zhang J, Bottaro DP, Pierce JH . Identification of serine 643 of protein kinase C-delta as an important autophosphorylation site for its enzymatic activity. J Biol Chem 1997; 272: 24550–24555.

    CAS  Article  PubMed  Google Scholar 

  21. Krappmann D, Patke A, Heissmeyer V, Scheidereit C . B-cell receptor- and phorbol ester-induced NF-kappaB and c-Jun N-terminal kinase activation in B cells requires novel protein kinase C's. Mol Cell Biol 2001; 21: 6640–6650.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Page K, Li J, Zhou L, Iasvovskaia S, Corbit KC, Soh JW et al. Regulation of airway epithelial cell NF-kappa B-dependent gene expression by protein kinase C delta. J Immunol 2003; 170: 5681–5689.

    CAS  Article  PubMed  Google Scholar 

  23. Minami T, Abid MR, Zhang J, King G, Kodama T, Aird WC . Thrombin stimulation of vascular adhesion molecule-1 in endothelial cells is mediated by protein kinase C (PKC)-delta-NF-kappa B and PKC-zeta-GATA signaling pathways. J Biol Chem 2003; 278: 6976–6984.

    CAS  Article  PubMed  Google Scholar 

  24. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994; 199: 93–98.

    CAS  Article  PubMed  Google Scholar 

  25. Chintalgattu V, Katwa LC . Role of protein kinase Cdelta in endothelin-induced type I collagen expression in cardiac myofibroblasts isolated from the site of myocardial infarction. J Pharmacol Exp Ther 2004; 311: 691–699.

    CAS  Article  PubMed  Google Scholar 

  26. Tseng CP, Kim YJ, Kumar R, Verma AK . Involvement of protein kinase C in the transcriptional regulation of 12-O-tetradecanoylphorbol-13-acetate-inducible genes modulated by AP-1 or non-AP-1 transacting factors. Carcinogenesis 1994; 15: 707–711.

    CAS  Article  PubMed  Google Scholar 

  27. Iglesias-Serret D, Pique M, Gil J, Pons G, Lopez JM . Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 2003; 417: 141–152.

    CAS  Article  PubMed  Google Scholar 

  28. Wang Q, Wang X, Evers BM . Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 2003; 278: 51091–51099.

    CAS  Article  PubMed  Google Scholar 

  29. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811–814.

    CAS  Article  PubMed  Google Scholar 

  30. Gandhi V, Huang P, Plunkett W . Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma 1994; 14 (Suppl 2): 3–9.

    Article  PubMed  Google Scholar 

  31. Vilpo J, Vilpo L . Selective toxicity of vincristine against chronic lymphocytic leukaemia in vitro. The Tampere CLL Group. Lancet 1996; 347: 1491–1492.

    CAS  Article  PubMed  Google Scholar 

  32. Malik IA, Costea NV . Verapamil preferentially potentiates in vitro cytotoxicity of vincristine on malignant lymphoid cells. Hematol Oncol 1992; 10: 225–231.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a research grant from the Technical university of Munich (KKF 15-00) and a grant from the Deutsche Forschungsgemeinschaft DE 771.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I Ringshausen.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu/)

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ringshausen, I., Oelsner, M., Weick, K. et al. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 20, 514–520 (2006). https://doi.org/10.1038/sj.leu.2404113

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404113

Keywords

  • B-CLL
  • signal transduction
  • PKC-δ
  • target therapy

Further reading

Search

Quick links